Thanks @Quiltman, that's interesting reading. I noticed that they seem to think it works in a sub group's of patients who hadn't previously taken Relyvrio. Another nail in the coffin for Amylyx' drug. I wonder what SLS-005's phase 1 results looked like and how many patients they had to gain ODD from the FDA?
It highlights how a phase 2/3 can uncover unknown issues when a greater number of patients with different histories are trialed. I wonder if any of our phase1 patients had ever been on Relyvrio?
Thanks @Quiltman, that's interesting reading. I noticed that...
-
- There are more pages in this discussion • 46 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NUZ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.5¢ |
Change
-0.015(6.25%) |
Mkt cap ! $109.4M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 24.0¢ | 22.5¢ | $133.9K | 573.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 303213 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.0¢ | 57592 | 2 |
View Market Depth
| Last trade - 15.46pm 18/10/2024 (20 minute delay) ? |
| NUZ (ASX) Chart |